Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Vitamin B12 injection receives drug registration approval from the US FDA.

Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Vitamin B12 Injection, 1000mcg/mL, 10,000mcg/10mL (1,000mcg/mL), 30,000mcg/30mL (1,000mcg/mL) (ANDA number: 214316). As of now, the company has invested approximately 27.0121 million RMB in the research and development of the Vitamin B12 Injection project. The newly approved product will be launched in the U.S. market in the near future, and is expected to have a positive impact on the company's business performance.